WGU D345 Psychopharmacology for Advanced
Psychiatric Mental Health Practice – Post-Master’s
Certificate Nursing PMHNP Study Guide, Original
Practice Questions & Answers, D345 Assessment
Preparation, Comprehensive Psychopharmacology
Review, Psychiatric Medications, Pharmacokinetics
& Pharmacodynamics, Addiction & Substance Use,
Medication Management, Patient Education, Safe
Prescribing & Advanced PMHNP Practice
Question 1: A psychiatric-mental health nurse practitioner (PMHNP) is
explaining to a patient that a prescribed medication will need to be taken for
several days before it reaches its full effect. What fundamental
pharmacokinetic principle is the PMHNP describing?
A. The drug's therapeutic index
B. The drug's half-life and time to reach steady-state concentration
C. The drug's bioavailability
D. The drug's volume of distribution
CORRECT ANSWER: B. The drug's half-life and time to reach steady-state
concentration
Rationale: Steady-state is the point at which drug intake and elimination are balanced,
and it is typically reached after 4-5 half-lives of the drug. This explains why the
medication takes several days to achieve its full therapeutic effect .
Question 2: A patient with a diagnosis of bipolar disorder is prescribed
lithium. The PMHNP explains that lithium's mechanism of action involves
modulating neurotransmitter activity. What is a primary effect of lithium on
neurotransmission?
A. It enhances the reuptake of serotonin and norepinephrine.
B. It is an antagonist at dopamine D2 receptors.
C. It inhibits excitatory neurotransmitters such as dopamine and glutamate.
D. It acts as a GABA-A receptor agonist.
CORRECT ANSWER: C. It inhibits excitatory neurotransmitters such as
dopamine and glutamate.
Rationale: Lithium supports mood stabilization through its inhibitory effects on
excitatory neurotransmitters, including dopamine and glutamate, and promotes GABA-
mediated neurotransmission .
,Question 3: A PMHNP is considering prescribing an antidepressant for a
patient with major depressive disorder. The PMHNP knows that the sequential
integration of psychotherapy following response to acute-phase
pharmacotherapy has been shown to have what benefit?
A. It is no more effective than pharmacotherapy alone.
B. It is associated with a reduced risk of relapse and recurrence.
C. It primarily serves to increase patient satisfaction.
D. It is the first-line treatment for severe MDD.
CORRECT ANSWER: B. It is associated with a reduced risk of relapse and
recurrence.
Rationale: A systematic review and meta-analysis by Guidi and Fava (2021) indicated
that the sequential integration of psychotherapy following a response to acute-phase
pharmacotherapy was associated with a reduced risk of relapse and recurrence in major
depressive disorder .
Question 4: A PMHNP is prescribing a medication that is highly protein-bound.
The patient has a history of liver disease resulting in hypoalbuminemia. What
effect should the PMHNP anticipate?
A. A decreased drug effect due to reduced protein binding.
B. An increased risk of drug toxicity due to increased free drug concentration.
C. No change in the drug's therapeutic effect.
D. A significant decrease in drug absorption from the GI tract.
CORRECT ANSWER: B. An increased risk of drug toxicity due to increased free
drug concentration.
Rationale: Highly protein-bound medications are primarily bound to albumin. In
hypoalbuminemia, there are fewer protein binding sites available, leading to a higher
concentration of the free (unbound) and pharmacologically active drug, which can result
in increased drug effects and toxicity .
Question 5: What distinguishes the professional role of the psychiatric-mental
health nurse practitioner (PMHNP) from other healthcare providers?
A. The ability to prescribe scheduled medications.
B. A primary focus on inpatient psychiatric care.
C. Advanced training in the combined use of pharmaceuticals and psychotherapy.
D. The exclusive use of cognitive-behavioral therapy.
CORRECT ANSWER: C. Advanced training in the combined use of
pharmaceuticals and psychotherapy.
,Rationale: The PMHNP is uniquely qualified to provide both treatment modalities using
pharmaceuticals and psychotherapy .
Question 6: A patient with generalized anxiety disorder (GAD) has not
responded to first-line treatments and is now being evaluated for a second-
generation antipsychotic. Which mechanism of action is characteristic of
atypical antipsychotics like aripiprazole?
A. 5-HT2A antagonism and D2 partial agonism
B. 5-HT1A antagonism and D2 full antagonism
C. 5-HT2A agonism and D2 full agonism
D. 5-HT1A agonism and D2 antagonism
CORRECT ANSWER: A. 5-HT2A antagonism and D2 partial agonism
Rationale: 5-HT2A antagonism, which helps balance dopamine signaling, in
combination with D2 partial agonism or antagonism, is a key characteristic that
distinguishes second-generation (atypical) antipsychotics .
Question 7: A PMHNP is evaluating a patient who reports a history of
medication-induced syndrome of inappropriate antidiuretic hormone secretion
(SIADH). Which FDA-indicated medication for bipolar disorder is known to
cause this adverse effect?
A. Lithium (Eskalith)
B. Lamotrigine (Lamictal)
C. Carbamazepine (Equetro)
D. Valproic acid (Depakote)
CORRECT ANSWER: C. Carbamazepine (Equetro)
Rationale: Carbamazepine can cause SIADH, which is characterized by impaired water
excretion leading to hyponatremia. To assess for SIADH, the NP would monitor the
patient's urine and plasma sodium levels, as well as urine and serum osmolality .
Question 8: A patient with chronic insomnia has been taking zolpidem
(Ambien) for several months. The PMHNP considers switching to a first-line
recommended treatment. According to clinical practice guidelines, which
medication is a first-line option for insomnia?
A. Diphenhydramine (Benadryl)
B. Zolpidem (Ambien)
C. Suvorexant (Belsomra)
D. Alprazolam (Xanax)
, CORRECT ANSWER: C. Suvorexant (Belsomra)
Rationale: Suvorexant is a first-line recommended treatment for insomnia per clinical
practice guidelines, in contrast to zolpidem which is second-line .
Question 9: A 16-year-old male patient presents with symptoms of major
depressive disorder, including depressed mood, fatigue, and suicidal ideation.
He has been symptomatic for a month and is experiencing a significant
deterioration in functioning. Which medication is FDA-approved for depression
in this age group and should be the first choice for the PMHNP?
A. Sertraline (Zoloft)
B. Fluoxetine (Prozac)
C. Paroxetine (Paxil)
D. Duloxetine (Cymbalta)
CORRECT ANSWER: B. Fluoxetine (Prozac)
Rationale: Fluoxetine is FDA-approved for the treatment of depression in adolescent
patients, making it a safe and appropriate first-line pharmacologic choice for this 16-
year-old patient .
Question 10: A PMHNP is treating a 52-year-old patient with bipolar disorder,
mixed features. The patient is on several medications and the PMHNP learns
that a medication must be tapered slowly due to a short half-life and risk of
withdrawal. Which medication is known to require a slow taper?
A. Fluoxetine (Prozac)
B. Gabapentin
C. Lithium
D. Lamotrigine (Lamictal)
CORRECT ANSWER: B. Gabapentin
Rationale: Gabapentin requires a taper because of its short half-life of 5-7 hours. Patients
can experience withdrawal effects, both physically and psychologically, with abrupt
discontinuation .
Question 11: A PMHNP is caring for a patient with borderline personality
disorder who experiences intense anxiety when the PMHNP goes on vacation.
This reaction is best explained by the patient's failure to master which
concept?
A. Object constancy
B. Primitive idealization
Psychiatric Mental Health Practice – Post-Master’s
Certificate Nursing PMHNP Study Guide, Original
Practice Questions & Answers, D345 Assessment
Preparation, Comprehensive Psychopharmacology
Review, Psychiatric Medications, Pharmacokinetics
& Pharmacodynamics, Addiction & Substance Use,
Medication Management, Patient Education, Safe
Prescribing & Advanced PMHNP Practice
Question 1: A psychiatric-mental health nurse practitioner (PMHNP) is
explaining to a patient that a prescribed medication will need to be taken for
several days before it reaches its full effect. What fundamental
pharmacokinetic principle is the PMHNP describing?
A. The drug's therapeutic index
B. The drug's half-life and time to reach steady-state concentration
C. The drug's bioavailability
D. The drug's volume of distribution
CORRECT ANSWER: B. The drug's half-life and time to reach steady-state
concentration
Rationale: Steady-state is the point at which drug intake and elimination are balanced,
and it is typically reached after 4-5 half-lives of the drug. This explains why the
medication takes several days to achieve its full therapeutic effect .
Question 2: A patient with a diagnosis of bipolar disorder is prescribed
lithium. The PMHNP explains that lithium's mechanism of action involves
modulating neurotransmitter activity. What is a primary effect of lithium on
neurotransmission?
A. It enhances the reuptake of serotonin and norepinephrine.
B. It is an antagonist at dopamine D2 receptors.
C. It inhibits excitatory neurotransmitters such as dopamine and glutamate.
D. It acts as a GABA-A receptor agonist.
CORRECT ANSWER: C. It inhibits excitatory neurotransmitters such as
dopamine and glutamate.
Rationale: Lithium supports mood stabilization through its inhibitory effects on
excitatory neurotransmitters, including dopamine and glutamate, and promotes GABA-
mediated neurotransmission .
,Question 3: A PMHNP is considering prescribing an antidepressant for a
patient with major depressive disorder. The PMHNP knows that the sequential
integration of psychotherapy following response to acute-phase
pharmacotherapy has been shown to have what benefit?
A. It is no more effective than pharmacotherapy alone.
B. It is associated with a reduced risk of relapse and recurrence.
C. It primarily serves to increase patient satisfaction.
D. It is the first-line treatment for severe MDD.
CORRECT ANSWER: B. It is associated with a reduced risk of relapse and
recurrence.
Rationale: A systematic review and meta-analysis by Guidi and Fava (2021) indicated
that the sequential integration of psychotherapy following a response to acute-phase
pharmacotherapy was associated with a reduced risk of relapse and recurrence in major
depressive disorder .
Question 4: A PMHNP is prescribing a medication that is highly protein-bound.
The patient has a history of liver disease resulting in hypoalbuminemia. What
effect should the PMHNP anticipate?
A. A decreased drug effect due to reduced protein binding.
B. An increased risk of drug toxicity due to increased free drug concentration.
C. No change in the drug's therapeutic effect.
D. A significant decrease in drug absorption from the GI tract.
CORRECT ANSWER: B. An increased risk of drug toxicity due to increased free
drug concentration.
Rationale: Highly protein-bound medications are primarily bound to albumin. In
hypoalbuminemia, there are fewer protein binding sites available, leading to a higher
concentration of the free (unbound) and pharmacologically active drug, which can result
in increased drug effects and toxicity .
Question 5: What distinguishes the professional role of the psychiatric-mental
health nurse practitioner (PMHNP) from other healthcare providers?
A. The ability to prescribe scheduled medications.
B. A primary focus on inpatient psychiatric care.
C. Advanced training in the combined use of pharmaceuticals and psychotherapy.
D. The exclusive use of cognitive-behavioral therapy.
CORRECT ANSWER: C. Advanced training in the combined use of
pharmaceuticals and psychotherapy.
,Rationale: The PMHNP is uniquely qualified to provide both treatment modalities using
pharmaceuticals and psychotherapy .
Question 6: A patient with generalized anxiety disorder (GAD) has not
responded to first-line treatments and is now being evaluated for a second-
generation antipsychotic. Which mechanism of action is characteristic of
atypical antipsychotics like aripiprazole?
A. 5-HT2A antagonism and D2 partial agonism
B. 5-HT1A antagonism and D2 full antagonism
C. 5-HT2A agonism and D2 full agonism
D. 5-HT1A agonism and D2 antagonism
CORRECT ANSWER: A. 5-HT2A antagonism and D2 partial agonism
Rationale: 5-HT2A antagonism, which helps balance dopamine signaling, in
combination with D2 partial agonism or antagonism, is a key characteristic that
distinguishes second-generation (atypical) antipsychotics .
Question 7: A PMHNP is evaluating a patient who reports a history of
medication-induced syndrome of inappropriate antidiuretic hormone secretion
(SIADH). Which FDA-indicated medication for bipolar disorder is known to
cause this adverse effect?
A. Lithium (Eskalith)
B. Lamotrigine (Lamictal)
C. Carbamazepine (Equetro)
D. Valproic acid (Depakote)
CORRECT ANSWER: C. Carbamazepine (Equetro)
Rationale: Carbamazepine can cause SIADH, which is characterized by impaired water
excretion leading to hyponatremia. To assess for SIADH, the NP would monitor the
patient's urine and plasma sodium levels, as well as urine and serum osmolality .
Question 8: A patient with chronic insomnia has been taking zolpidem
(Ambien) for several months. The PMHNP considers switching to a first-line
recommended treatment. According to clinical practice guidelines, which
medication is a first-line option for insomnia?
A. Diphenhydramine (Benadryl)
B. Zolpidem (Ambien)
C. Suvorexant (Belsomra)
D. Alprazolam (Xanax)
, CORRECT ANSWER: C. Suvorexant (Belsomra)
Rationale: Suvorexant is a first-line recommended treatment for insomnia per clinical
practice guidelines, in contrast to zolpidem which is second-line .
Question 9: A 16-year-old male patient presents with symptoms of major
depressive disorder, including depressed mood, fatigue, and suicidal ideation.
He has been symptomatic for a month and is experiencing a significant
deterioration in functioning. Which medication is FDA-approved for depression
in this age group and should be the first choice for the PMHNP?
A. Sertraline (Zoloft)
B. Fluoxetine (Prozac)
C. Paroxetine (Paxil)
D. Duloxetine (Cymbalta)
CORRECT ANSWER: B. Fluoxetine (Prozac)
Rationale: Fluoxetine is FDA-approved for the treatment of depression in adolescent
patients, making it a safe and appropriate first-line pharmacologic choice for this 16-
year-old patient .
Question 10: A PMHNP is treating a 52-year-old patient with bipolar disorder,
mixed features. The patient is on several medications and the PMHNP learns
that a medication must be tapered slowly due to a short half-life and risk of
withdrawal. Which medication is known to require a slow taper?
A. Fluoxetine (Prozac)
B. Gabapentin
C. Lithium
D. Lamotrigine (Lamictal)
CORRECT ANSWER: B. Gabapentin
Rationale: Gabapentin requires a taper because of its short half-life of 5-7 hours. Patients
can experience withdrawal effects, both physically and psychologically, with abrupt
discontinuation .
Question 11: A PMHNP is caring for a patient with borderline personality
disorder who experiences intense anxiety when the PMHNP goes on vacation.
This reaction is best explained by the patient's failure to master which
concept?
A. Object constancy
B. Primitive idealization
